Find the Right Companion Diagnostic

Vysis ALK Break Apart FISH Probe Kit is an FDA-approved, dual-color fluorescence in situ hybridization assay that uses break-apart DNA probes targeting the ALK locus in FFPE non–small cell lung cancer tissue. By detecting split or isolated ALK signals, it identifies ALK gene rearrangements and classifies tumors as ALK positive or negative to guide ALK-directed treatment strategies.

Oncomine Dx Target Test is an FDA-approved, qualitative targeted NGS assay performed on the Ion PGM Dx System. Using DNA and RNA from FFPE tumor tissue, it detects single-nucleotide variants, insertions, deletions, and fusions in a defined panel of cancer driver genes. It is approved for use in NSCLC and several other solid tumors to characterize oncogenic alterations and support selection of targeted treatment strategies.

MMR IHC Panel pharmDx is an FDA-approved, qualitative immunohistochemical assay performed on the Dako Omnis platform to assess MLH1, PMS2, MSH2, and MSH6 protein expression in FFPE colorectal cancer tissue. By determining mismatch repair–deficient (dMMR) status based on loss of nuclear staining, it helps identify patients who may be candidates for immunotherapy.